“We are very pleased with the continued development of the patent portfolio for Oncoral and view the decision of the USPTO as recognition of the innovation behind our novel oral formulation of irinotecan. The opportunity to strengthen the patent protection for Oncoral adds further value to the development and commercialization opportunities for Oncoral and for Ascelia Pharma”, said Julie Waras Brogren, Deputy CEO and Chief Commercial Officer of
The new patent covers the tablet composition and will provide protection until 2035 plus potential extension in the US. It broadens the scope of Ascelia Pharma’s patent protection for Oncoral beyond the already-granted US patents US 10,143,657 and US 11,419,825, which broadly cover the solid oral composition of Oncoral as well as the method of using Oncoral. Outside the US, Oncoral is covered by patents in selected European countries and in
© Modular Finance, source